Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Morphic Holding, Inc. (MORF : NSDQ)
 
 • Company Description   
Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.

Number of Employees: 101

 
 • Price / Volume Information   
Yesterday's Closing Price: $22.33 Daily Weekly Monthly
20 Day Moving Average: 565,501 shares
Shares Outstanding: 38.27 (millions)
Market Capitalization: $854.55 (millions)
Beta: 1.46
52 Week High: $68.75
52 Week Low: $21.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.91% -16.55%
12 Week -44.09% -38.53%
Year To Date -52.87% -42.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
35 Gatehouse Drive A2
-
Waltham,MA 02451
USA
ph: 781-996-0955
fax: -
None http://www.morphictx.com
 
 • General Corporate Information   
Officers
Praveen P. Tipirneni - President and Chief Executive Officer
Marc Schegerin - Chief Financial Officer and Chief Operating Office
Norbert Bischofberger - Director
Gustav Christensen - Director
Martin Edwards - Director

Peer Information
Morphic Holding, Inc. (CORR.)
Morphic Holding, Inc. (RSPI)
Morphic Holding, Inc. (CGXP)
Morphic Holding, Inc. (BGEN)
Morphic Holding, Inc. (GTBP)
Morphic Holding, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 61775R105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 38.27
Most Recent Split Date: (:1)
Beta: 1.46
Market Capitalization: $854.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.84 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.46 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.71
Price/Cash Flow: -
Price / Sales: 45.19
EPS Growth
vs. Year Ago Period: -34.92%
vs. Previous Quarter: -49.12%
Sales Growth
vs. Year Ago Period: -27.04%
vs. Previous Quarter: -75.07%
ROE
03/31/22 - -31.37
12/31/21 - -27.23
09/30/21 - -30.32
ROA
03/31/22 - -24.86
12/31/21 - -21.67
09/30/21 - -23.26
Current Ratio
03/31/22 - 8.89
12/31/21 - 10.93
09/30/21 - 10.43
Quick Ratio
03/31/22 - 8.89
12/31/21 - 10.93
09/30/21 - 10.43
Operating Margin
03/31/22 - -559.19
12/31/21 - -482.71
09/30/21 - -569.40
Net Margin
03/31/22 - -559.19
12/31/21 - -482.71
09/30/21 - -569.40
Pre-Tax Margin
03/31/22 - -559.19
12/31/21 - -482.68
09/30/21 - -570.28
Book Value
03/31/22 - 8.19
12/31/21 - 9.11
09/30/21 - 9.61
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©